Lv4
430 积分 2023-01-09 加入
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
2小时前
已完结
Shaping the future of cardiometabolic innovation: advances and opportunities
8天前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
1个月前
已完结
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
1个月前
已完结
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
1个月前
已完结
The nature and characteristics of hypertriglyceridemia in a large cohort with type 2 diabetes
1个月前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
1个月前
已完结
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
1个月前
已完结
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
2个月前
已完结
皖公网安备34019202002308
